Terminology Service for NFDI4Health
All terms in BAO
| Label | Id | Description |
|---|---|---|
| endogenous ligand | BAO_0000022 | |
| LysoTracker Red | BAO_0000021 | |
| monoclonal | BAO_0000503 | [Highly specific antibodies produced by the clones of a single hybrid cell, which is generated by the fusion of a B cell with a tumor cell. They recognize a unique epitope of an antigen.] |
| tertiary structure | BAO_0000020 | |
| LYMP2-020 | BAO_0002680 | |
| LYMP2-022 | BAO_0002681 | |
| LYMP2-024 | BAO_0002682 | |
| U3A | BAO_0002683 | |
| assay screening campaign stage | BAO_0000029 | [The assay stage describes the purpose of the assay in an assay campaign. Assay stage also relates to the order of assays in a screening campaign. For example the primary assay, which is performed first, identifies hits. The primary hits are then confirmed in a confirmatory assay. Subsequent secondary assays are run to eliminate compounds that are not of interest or to confirm hits using an alternate design / technology, or to further characterize compounds. Whether an assay is run in single concentration or concentration response is defined in the class 'assay measurement throughput quality'. For example primary assays are typically run in single concentration with single measurements. However, the NCGC runs qHTS primary assays as concentration-response assays.] |
| LYMP2-026 | BAO_0002684 | |
| assay quality assessment method | BAO_0000028 | [Commonly used statistical parameters for monitoring assay quality include Z and Z' factors. Prior to starting a large screen, and after assay optimization and miniaturization, pilot screens are performed to assess the quality of the assay run and to assess / validate the suitability of a assay for a high-throughput screening run.] |
| MV-4-11 | BAO_0002685 | |
| assay provider | BAO_0000027 | [The role of a scientist who has designed an assay and requested it to be run at a screening center.] |
| researcher role | BAO_0002900 | |
| LYMP2-007 | BAO_0002686 | |
| LYMP2-006 | BAO_0002687 | |
| hepatitis C virus nonstructural protein 5A inhibitor | CHEBI_85185 | |
| WAGR syndrome | DOID_14515 | [A chromosomal deletion syndrome that is a nephroblastoma that results_in a rare genetic syndrome in which affected children are predisposed to develop Wilms tumor, Aniridia (absence of the colored part of the eye, the iris), genitourinary anomalies, and mental retardation. The condition results from a deletion on chromosome 11 resulting in the loss of several genes. As such, it is one of the best studied examples of a condition caused by loss of neighbouring (contiguous) genes.] |
| chromosomal deletion syndrome | DOID_0060388 | |
| LYMP2-004 | BAO_0002699 |